Why Recursion Pharmaceuticals Is On Investors’ Radar Recursion Pharmaceuticals (RXRX) has been drawing attention after recent ...

And its investments in AI could, eventually, lead to important monetization opportunities even beyond advertising, perhaps ...

Wondering if Recursion Pharmaceuticals at around US$4.67 a share is priced for its potential or still misunderstood by the ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $4.65, demonstrating a -4.12% change from the preceding day's closing price. This move lagged the S&P 500's daily gain of 0.26%.

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to beat earnings when it reports second-quarter 2025 results on Aug. 5 ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

The concept of a meme stock was born about five years ago. It refers to a publicly traded company that gains substantial market value practically overnight (sometimes literally) due to significant ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Recursion Pharmaceuticals (RXRX) closed at $4.7 in the latest trading session, marking a -3.29% move from the prior day.

One person that helped bring the chill was an analyst cutting his price target. Another two were executives at the biotech selling chunks of stock. The company was the target of an analyst price ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.